

AMENDMENTS TO THE CLAIMS

Claims 21-32 are pending, of which claims 25-29 are withdrawn.

Claims 22-32 are being canceled, and new claim 33 is being added.

After the amendments, claims 21 and 33 will be pending.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-20. (Canceled)

21. (Previously presented) An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide encoded by a nucleic acid molecule having SEQ ID NO: 3; and
- (b) a polypeptide encoded by a nucleic acid molecule which hybridizes to the complement of the polynucleotide having SEQ ID NO: 3 under conditions of about 100 mM salt and 60°C, wherein said polypeptide is capable of binding a human IL-B50 receptor.

22.-32. (Canceled)

33. (New) An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide encoded by a nucleic acid molecule having SEQ ID NO:1; and
- (b) a polypeptide encoded by a nucleic acid molecule which hybridizes to the complement of the polynucleotide having SEQ ID NO:1 under conditions of about 100 mM salt and 60°C, wherein said polypeptide is capable of binding a human IL-B50 receptor.